Additionally, targeting antigens such as CD123 and CD33 that are shared by leukemic cells and hematopoietic stem cells makes on-target off-leukemia toxicities a significant limiting aspect of treatment, reducing the efficacy of cell therapy while magnifying the potential for systemic off-tumor toxicities. This evidence concerns the gene CD33 and neoplasm.